Climb Bio Financials
This page shows Climb Bio (CLYM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Climb Bio passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Climb Bio generates $0.21 in operating cash flow (-$15.6M OCF vs -$73.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Climb Bio generated -$20.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 1.9% from the prior year.
Climb Bio reported -$73.9M in net income in fiscal year 2024. This represents a decrease of 110.4% from the prior year.
Climb Bio earned $-1.53 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 17.7% from the prior year.
Climb Bio held $87.2M in cash against $0 in long-term debt as of fiscal year 2024.
Climb Bio had 67M shares outstanding in fiscal year 2024. This represents an increase of 142.8% from the prior year.
Climb Bio invested $14.2M in research and development in fiscal year 2024. This represents a decrease of 8.0% from the prior year.
Climb Bio invested $4.6M in capex in fiscal year 2024, funding long-term assets and infrastructure.
CLYM Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $9.1M+45.4% | $6.2M | N/A | $2.9M-22.0% | $3.7M-35.5% | $5.7M | N/A | $4.3M |
| SG&A Expenses | $5.8M+6.0% | $5.5M | N/A | $2.1M-29.8% | $3.0M-82.9% | $17.7M | N/A | $4.5M |
| Operating Income | -$14.9M-26.9% | -$11.7M | N/A | -$5.0M+25.5% | -$6.7M+71.4% | -$23.4M | N/A | -$8.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $0 | N/A | $0 | N/A | N/A |
| Net Income | -$12.9M-44.9% | -$8.9M | N/A | -$4.0M+24.0% | -$5.2M+76.6% | -$22.3M | N/A | -$9.7M |
| EPS (Diluted) | $-0.19-46.2% | $-0.13 | N/A | $-0.15+21.1% | $-0.19+77.4% | $-0.84 | N/A | $-0.37 |
CLYM Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $182.3M-16.1% | $217.2M+96.6% | $110.5M-2.0% | $112.7M-3.0% | $116.3M-4.8% | $122.1M-9.6% | $135.0M-4.2% | $140.9M |
| Current Assets | $91.0M-41.3% | $154.9M+40.5% | $110.3M-1.9% | $112.4M-1.6% | $114.2M-4.9% | $120.2M-10.6% | $134.4M+0.9% | $133.2M |
| Cash & Equivalents | $25.8M-70.4% | $87.2M-6.3% | $93.1M+62.3% | $57.4M+126.7% | $25.3M-26.5% | $34.4M-21.0% | $43.6M+21.3% | $35.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.3M-0.1% | $5.3M+84.9% | $2.9M-4.1% | $3.0M-20.7% | $3.8M-27.8% | $5.2M-16.8% | $6.3M-3.4% | $6.5M |
| Current Liabilities | $4.9M+0.4% | $4.9M+74.1% | $2.8M-2.3% | $2.9M-19.8% | $3.6M-26.4% | $4.9M-19.4% | $6.1M-2.9% | $6.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $177.0M-16.5% | $211.9M+96.9% | $107.6M-2.0% | $109.7M-2.5% | $112.5M-3.7% | $116.9M-9.2% | $128.7M-4.2% | $134.4M |
| Retained Earnings | -$272.2M-18.4% | -$229.9M-47.4% | -$156.0M-2.4% | -$152.3M-2.7% | -$148.4M-3.6% | -$143.2M-18.4% | -$120.9M-6.9% | -$113.1M |
CLYM Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.1M-119.9% | -$5.5M-483.0% | -$947K-127.1% | $3.5M+143.8% | -$8.0M+47.5% | -$15.2M-79.6% | -$8.4M-102.4% | -$4.2M |
| Capital Expenditures | $109K-97.7% | $4.6M | $0 | $0 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$12.2M-20.5% | -$10.2M-973.5% | -$947K-127.1% | $3.5M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $15.3M+128.6% | -$53.4M-245.3% | $36.7M+31.1% | $28.0M+1851.2% | -$1.6M-127.6% | $5.8M-59.4% | $14.3M+67.8% | $8.5M |
| Financing Cash Flow | $0-100.0% | $41K-85.8% | $288K-45.5% | $528K+2100.0% | $24K+2300.0% | $1K | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CLYM Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -7.1%-3.1pp | -4.0% | N/A | -3.5%+1.0pp | -4.5%+13.8pp | -18.3% | N/A | -6.9% |
| Current Ratio | 18.38-13.0 | 31.41-7.5 | 38.92+0.2 | 38.76+7.2 | 31.58+7.1 | 24.45+2.4 | 22.04+0.8 | 21.21 |
| Debt-to-Equity | 0.030.0 | 0.030.0 | 0.030.0 | 0.030.0 | 0.03-0.0 | 0.040.0 | 0.050.0 | 0.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Climb Bio profitable?
No, Climb Bio (CLYM) reported a net income of -$73.9M in fiscal year 2024.
What is Climb Bio's earnings per share (EPS)?
Climb Bio (CLYM) reported diluted earnings per share of $-1.53 for fiscal year 2024. This represents a -17.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Climb Bio's free cash flow?
Climb Bio (CLYM) generated -$20.2M in free cash flow during fiscal year 2024. This represents a 1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Climb Bio's operating cash flow?
Climb Bio (CLYM) generated -$15.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Climb Bio's total assets?
Climb Bio (CLYM) had $217.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Climb Bio's capital expenditures?
Climb Bio (CLYM) invested $4.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Climb Bio spend on research and development?
Climb Bio (CLYM) invested $14.2M in research and development during fiscal year 2024.
How many shares does Climb Bio have outstanding?
Climb Bio (CLYM) had 67M shares outstanding as of fiscal year 2024.
What is Climb Bio's current ratio?
Climb Bio (CLYM) had a current ratio of 31.41 as of fiscal year 2024, which is generally considered healthy.
What is Climb Bio's debt-to-equity ratio?
Climb Bio (CLYM) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Climb Bio's return on assets (ROA)?
Climb Bio (CLYM) had a return on assets of -34.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Climb Bio's cash runway?
Based on fiscal year 2024 data, Climb Bio (CLYM) had $87.2M in cash against an annual operating cash burn of $15.6M. This gives an estimated cash runway of approximately 67 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Climb Bio's Piotroski F-Score?
Climb Bio (CLYM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Climb Bio's earnings high quality?
Climb Bio (CLYM) has an earnings quality ratio of 0.21x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.